Navigation Links
Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009
Date:5/1/2008

- Company Announces $60 Million Share Repurchase Authorization -

BRAINTREE, Mass., May 1 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) today reported fourth quarter fiscal 2008 GAAP net revenues of $139 million, up 19%; operating income of $20 million, down 21%; and net earnings per share of $0.52, down 29%. The Company also reported fiscal year end 2008 GAAP net revenues of $516 million, up 15%; operating income of $70 million, up 12%, and net earnings per share of $1.94, up 9%.

Excluding charges in both fiscal 2007 and 2008 and a legal settlement and certain tax benefits in 2007, fourth quarter fiscal 2008 adjusted operating income was $23 million, up 10%, and adjusted earnings per share were $0.58, level with prior year. Full year 2008 adjusted operating income was $77 million, up 10%, and adjusted earnings per share were $2.10, up 10%.(1)

Brad Nutter, Haemonetics' Chairman and CEO, said, "I am pleased to report four consecutive quarters of double digit revenue growth and double digit growth in adjusted operating income and adjusted earnings per share for the year. Growth continues to come from strength across multiple product lines and geographies, and we have a positive outlook for all these markets."

"In the year, we made good strides in our vision to be the global leader in blood management solutions for our customers. We introduced several new products in both the blood bank and hospital markets. We acquired a new device for patient blood management and a consulting and information technology platform for hospital blood management. Haemonetics now provides customers with a value proposition that includes the most extensive depth and breadth of devices, services, and information technoloBank $35,749 $32,218 11.0% 136,148 126,216 7.9%

Red Cell $12,120 $11,301 7.2% 46,377 43,406 6.8%

$88,299 $74,237 18.9% $337,744 $296,593 13.9%

Patient:

Surgical/Diagnostic $21,178 $17,254 22.7% 72,085 66,552 8.3%

OrthoPAT $9,179 $8,383 9.5% 34,301 30,515 12.4%

$30,357 $25,637 24.0% $106,386 $97,067 9.6%

Subtotal $118,656 $99,874 18.8% $444,130 $393,660 12.8%

Equipment $10,527 $7,022 49.9% $32,813 $22,229 47.6%

Software & Services $9,556 $10,023 (4.7%) 39,498 33,718 17.1%

Net Revenues $138,739 $116,919 18.7% $516,440 $449,607 14.9%

Consolidated Balance Sheets

Period ending

03/29/08 03/31/07

Assets

Cash & cash equivalents $133,553 $229,227

Accounts receivable, net $120,252 $91,832

Inventories, net $65,388 $61,797

Other current assets $32,881 $20,815

Total current assets $352,074 $403,671

Net PP&E $116,484 $90,775

Other assets $129,198 $78,289

Total assets $597,756 $572,735

Period ending

03/29/08 03/31/07

Liabilities & Stockholders' Equity

S/T debt & current maturities $6,326 $22,201

Other current liabilities 89,391 $59,816

Total current liabilities 95,717 82,017

Long-term debt 6,037 6,675

Other long-term liabilities 1,814 4,395

Stockholders' equity 494,188 479,648

Total liabilities & equity $597,756 $572,735

FREE CASH FLOW RECONCILIATION

FREE CASH FLOW RECONCILIATION: Three Months Ended Twelve Months Ended

3-29-08 3-31-07 3-29-08 3-31-07

GAAP CASH FLOW FROM OPERATIONS $30,414 $24,096 $76,168 $83,563

Capital expenditures ($16,223) ($13,453) ($56,800) ($40,438)

Proceeds from sale of property,

plant and equipment $605 $255 $1,834 $2,843

Net investment in property,

plant and equipment ($15,618) ($13,198) ($54,966) ($37,595)

Free Cash Flow $14,796 $10,898 $21,202 $45,968

RECONCILIATION OF NON-GAAP MEASURES

Haemonetics has presented supplemental non-GAAP financial measures as part of this earnings release. A reconciliation is provided below that reconciles each non-GAAP financial measure with the most comparable GAAP measure. The presentation of non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures. There are material limitations to the usefulness of non-GAAP measures on a standalone basis, including the lack of comparability to the GAAP financial results of other companies.

These measures are used by management to monitor the financial performance of the business, inform business decision making, and to forecast future results. Performance targets for management are established based upon these non-GAAP measures. In the reconciliations below we have removed restructuring costs from our GAAP expenses. These restructuring costs result from a significant transformation of our International businesses during our fiscal years 2008 and 2007. This transformation resulted in the formation of a shared service center in Europe, and exiting various offices across Europe, and Japan. We have also removed In-Process research and development expenses associated with the acquisition of Arryx, Inc. in FY07. Additionally, we removed the receipt of an award resulting from a net settlement agreement against a competitor in FY07. Lastly removed is the impact of a reduction to income tax due to the finalization of an audit of prior year income tax returns in FY07. We believe this information is useful for investors because it allows for an evaluation of the Company with a focus on the performance of our core operations.

-- Non-GAAP S,G&A and Non-GAAP Operating Expenses

The use of this non-GAAP measure allows management to monitor the

ongoing level of spend that is necessary to support the business in a

period when we are not transforming our business, or completing an

acquisition of in-process research and development. We establish our

budgets, forecasts, and performance targets excluding these costs.

-- Non-GAAP Operating Income and Non-GAAP Income Before Income Taxes

The use of these non-GAAP measures allows management to monitor the

level of operating and total pre-tax profits without the costs of our

business transformation or in-process research and development costs.

We establish our budgets, forecasts, and performance targets on this

basis.

-- Non-GAAP Operating Income and Non-GAAP Income Before Income Taxes

The use of these non-GAAP measures allows management to monitor the

level of operating and total pre-tax profits without the costs of our

business transformation or in-process research and development costs.

We establish our budgets, forecasts, and performance targets on this

basis.

-- Non-GAAP Net Income and Earnings Per Share

The use of these non-GAAP measures allows management to monitor the

level of net income and earnings per share excluding both the costs of

our business transformation, in-process research and development costs,

as well as any related tax effects, and the favorable resolution of an

audit of prior year tax returns. We establish our budgets, forecasts,

and performance targets on this basis. Reconciliation of Non-GAAP Measures for the Fourth Quarter FY08 and FY07

03/29/08 03/31/07

Non-GAAP S,G&A

GAAP S,G&A $44,042 $31,815

Restructuring Costs (2,384) (586)

Non-GAAP S,G&A $41,658 $31,229

Non-GAAP Operating expenses

GAAP Operating Expenses $49,832 $32,655

Restructuring Costs (2,384) (586)

Baxter PI Settlement 5,700

Non-GAAP Operating Expenses $47,448 $37,769

Non-GAAP Operating income

GAAP Operating Income $20,309 $25,691

Restructuring Costs 2,384 586

Baxter PI Settlement (5,700)

Non-GAAP Operating income $22,693 $20,577

Non-GAAP Income before taxes

GAAP Income before taxes $21,382 $28,415

Restructuring Costs 2,384 586

Baxter PI Settlement (5,700)

Non-GAAP Income before taxes $23,766 $23,301

Non-GAAP Net Income

GAAP Net Income $13,793 $19,784

Restructuring Costs 2,384 586

Baxter PI Settlement (5,700)

Tax benefit associated with Restructuring Costs (847) (176)

Tax benefit associated with Baxter PI Settlement 1,721

Resolution of Tax Contingencies (399)

Non-GAAP NET INCOME $15,330 $15,816

Non-GAAP Net Income per common

share assuming dilution

GAAP Net Income per common share assuming

dilution $0.52 $0.72

Restructuring Costs after tax per common share

assuming dilution $0.06 $0.02

Baxter PI Settlement per common share assuming

dilution $0.00 ($0.15)

Resolution of Tax Contingencies per common share

assuming dilution $0.00 ($0.01)

Non-GAAP Net Income per common share assuming

dilution $0.58 $0.58

Reconciliation of Non-GAAP Measures for the Full Year FY08 and FY07

03/29/08 03/31/07

Non-GAAP S,G&A

GAAP S,G&A $163,116 $137,073

Restructuring Costs (6,307) (3,518)

Non-GAAP S,G&A $156,809 $133,555

Non-GAAP Operating expenses

GAAP Operating Expenses $187,438 $164,555

Restructuring Costs (6,307) (3,518)

In-Process Research and Development (9,073)

Baxter PI Settlement 5,700

Non-GAAP Operating Expenses $181,131 $157,664

Non-GAAP Operating income

GAAP Operating Income $70,287 $62,745

Restructuring Costs 6,307 3,518

In-Process Research and Development 9,073

Baxter PI Settlement (5,700)

Non-GAAP Operating income $76,594 $69,636

Non-GAAP Income before taxes

GAAP Income before taxes $77,302 $72,336

Restructuring Costs 6,307 3,518

In-Process Research and Development 9,073

Baxter PI Settlement (5,700)

Non-GAAP Income before taxes $83,609 $79,227

Non-GAAP Net Income

GAAP Net Income $51,980 $49,109

Restructuring Costs 6,307 3,518

In-Process Research and Development 9,073

Baxter PI Settlement (5,700)

Tax benefit associated with Restructuring Costs (2,067) (1,180)

Tax benefit associated with Baxter PI Settlement 1,721

Resolution of Tax Contingencies (3,967)

Non-GAAP NET INCOME $56,220 $52,574

Non-GAAP Net Income per common

share assuming dilution

GAAP Net Income per common share assuming

dilution $1.94 $1.78

Restructuring Costs after tax per common share

assuming dilution $0.16 $0.09

In-Process Research and Development per common

share assuming dilution $0.00 $0.33

Baxter PI Settlement per common share assuming

dilution $0.00 ($0.15)

Resolution of Tax Contingencies per common share

assuming dilution $0.00 ($0.14)

Non-GAAP Net Income per common share

assuming dilution $2.10 $1.90

CONTACT:

Julie Fallon

Tel. (781) 356-9517

Alternate Tel. (617) 320-2401

fallon@haemonetics.com

gy platforms across the blood bank and hospital markets."

FINANCIALS

In addition to revenues and earnings per share, Haemonetics reported fourth quarter gross profit of $70 million, up 20%, and gross margin of 50.6%, up 70 basis points. For the year, gross profit was $258 million, up 13%, and gross margin was 49.9%, down 70 basis points. Gross margin was impacted by product mix as lower gross margin contributors, plasma and equipment, had very strong sales growth.

Adjusted operating expenses were $47 million in the quarter, up 26%, and $181 million for the year, up 15%. Nearly half of the year's increase came from three areas: 1) planned enterprise resource planning ("ERP") spending; 2) the acquisitions of IDM, Infonale, and Haemoscope, whose expenses were not included in most of fiscal 2007 financial results; and 3) continued investment in Arryx R&D.

Haemonetics' tax rate was 35.5% in the quarter and 32.8% for the year. In the year, Haemonetics benefited from resolution of certain tax contingencies.

Haemonetics ended the year with a cash balance of $134 million, and $12 million of debt. During the year, the Company generated $76 million of cash flow from operations and invested $57 million in capital expenditures to invest in ERP, the plasma business, and software development. In the year, the Company invested $75 million in a share repurchase and $46 million on acquisitions.

EXPANDING THE BUSINESS

Haemonetics continues to make progress expanding the business. The Company reported the following highlights during the fiscal year just ended:

-- Preferred provider contracts with Haema AG and Octapharma Europe in its

plasma business which can capitalize on ongoing collection market

growth

-- Expansion of an agreement with the U.S. Department of Defense for

information technology services that manage the Department of Defense's

blood standard system

-- Launch of a module for the Company's Symphony software suite that

allows blood bank customers to automate applications in their

manufacturing and distribution operations

-- Acquisition of the TEG(R) Thrombelastograph(R) Hemostasis Analyzer

business which is expected to add more than $16 million in annual

revenues

-- Acquisition of Infonale which gives Haemonetics strategic expertise in

hospital blood management consulting services

-- Restructuring of European and Asian operations which reported revenue

growth of 11% and 19%, respectively

-- Completion of Phase I of an enterprise resource planning initiative

which converted all geographies, sales, service and financial functions

to a new system

ANNUAL PRODUCT LINE GROWTH

Among the product lines, plasma disposables revenue was $40 million for the quarter, up 32%. Annual plasma disposables revenue was $155 million, up 22%. Plasma disposable sales benefited from continued growth in U.S. and European plasma collections as well as from Haemonetics' collection growth at new customer sites. Haemonetics expects that growth in the plasma market will continue to drive strong plasma sales for the next several years.

Blood bank disposables revenue was $36 million for the quarter, up 11%. Annual blood bank disposables revenue was $136 million, up 8%. Blood bank growth was driven by strong sales in Europe and Asia as the Company sees early benefits from last year's reorganization initiatives.

Red cell disposables revenue was $12 million for the quarter, up 7%. Annual red cell disposables revenue was $46 million, up 7%. Strong equipment sales of the newest generation Cymbal(R) automated blood collection system and the MCS(R)+ mobile collection system in the first half of the year drove strong product line sales. Including equipment, total revenues for the red cell product line grew 13% in the year.

Software and services revenue was $10 million for the quarter, down 5%. Annual software and services revenue was $39 million, up 17%. Software and services revenue growth in the year came from several areas: 1) the acquisition of IDM, Inc. in January 2007; 2) the integration of the Surround software suite into the operations of Hema Quebec, completing the integration of Surround into all Canadian blood testing; and 3) the ongoing management of and enhancements to the U.S. Department of Defense's Defense Blood Standard System.

Surgical disposables revenue was $21 million, up 23% for the quarter. Annual Surgical disposables revenue was $72 million, up 8%. Growth for the quarter and year was driven by the TEG product line which Haemonetics acquired in November 2007.

OrthoPAT(R) disposables revenue was $9 million for the quarter, up 10%. Annual OrthoPAT disposables revenue was $34 million, up 12%. The Company placed more than 175 OrthoPAT devices in the field in fiscal 2008. Equipment placements are expected to continue to drive disposables growth into fiscal 2009.

Equipment revenue was $11 million for the quarter, up 50%, and $33 million for the year, up 48%. Equipment sales growth was driven by sales of plasma devices in the growing European and Asian markets, platelet equipment in Europe, and red cell equipment in the U.S.

FISCAL 2009 SHARE REPURCHASE PLAN

Haemonetics said today that its Board of Directors has authorized a $60 million share repurchase program.

FISCAL 2009 GUIDANCE

Haemonetics announced its fiscal 2009 guidance. In fiscal 2009, the Company anticipates revenue growth of 8-11%, with growth again being driven by multiple product lines. Growth is planned from plasma, red cells, software, OrthoPAT, internal new products, and the acquired TEG product line. Adjusted operating income is expected to grow 14-17%, and adjusted earnings per share are expected to be in a range of $2.31 to $2.41, up 10-14%.

The Company further expects gross margin improvement of more than 150 basis points and operating margin improvement of 70 basis points in fiscal 2009.

Adjusted fiscal 2009 guidance excludes $7-8 million, or approximately $0.17-$0.20 per share, of costs to restructure other areas of Haemonetics' business, including manufacturing, quality, R&D, and Europe Phase II.

For the full year 2009, the Company expects to generate $40 million of free cash flow.

Fiscal 2009 GAAP earnings per share guidance is $2.14 to $2.21.

Haemonetics has posted potential income scenarios reflecting guidance ranges as well as potential fiscal 2009 product line growth on its website at http://www.haemonetics.com.

CONFERENCE CALL

Haemonetics will hold a conference call on Thursday, May 1st at 10:00 am Eastern to discuss these results. Interested parties can participate in the conference call by dialing 888-802-8577 (U.S. only) or (973) 935-8754 (International) with conference ID 42384135. The call will be replayed through May 15, 2008 at (800) 642-1687 (U.S. only) or (706) 645-9291 (International) using PIN 42384135.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

As part of this release, Haemonetics has presented supplemental non-GAAP financial results which exclude restructuring costs in FY08 and restructuring costs, an in-process research and development charge, a legal settlement and the resolution of an audit of a prior year tax return in FY07. Haemonetics believes that these non-GAAP results are useful to investors because it allows for an evaluation of the Company with a focus on the results of our core business.

This release contains forward-looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers' ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.

(1) The Company has attached a reconciliation of GAAP to adjusted results

at the end of this release. A copy of the reconciliation is also

posted on the web at http://www.haemonetics.com/investors.

Haemonetics Corporation Financial Summary

(Unaudited data in thousands, except per share data)

Consolidated Statements of Income for the Fourth Quarter FYE08

% Inc/(Dec)

3/29/08 As 3/31/07 As vs Prior

Reported Reported Year

NET REVENUES $138,739 $116,919 18.7%

Gross profit 70,141 58,346 20.2%

R&D 5,790 6,540 (11.5%)

S,G&A 44,042 31,815 38.4%

Arbitration and Settlement Income 0 (5,700) (100.0%)

In-Process R&D

Cost to Equity

Operating expenses 49,832 32,655 52.6%

Operating income 20,309 25,691 (20.9%)

Interest expense (24) (68) (64.7%)

Interest income 1,028 1,962 (47.6%)

Other income/(expense), net 69 830 (91.7%)

Income before taxes 21,382 28,415 (24.8%)

Tax expense 7,589 8,631 (12.1%)

NET INCOME $13,793 $19,784 (30.3%)

Net income per common share

assuming dilution $0.52 $0.72 (28.5%)

Weighted average number of shares

Basic 25,653 26,469

Diluted 26,602 27,313

Inc/(Dec) vs

prior year

profit

Profit Margins: margin %

Gross profit 50.6% 49.9% 0.7%

R&D 4.2% 5.6% (1.4%)

S,G&A 31.7% 27.2% 4.5%

Operating income 14.6% 22.0% (7.4%)

Income before taxes 15.4% 24.3% (8.9%)

Net income 9.9% 16.9% (7.0%)

Consolidated Statements of Income for FYE08 YTD

% Inc/(Dec)

3/29/08 As 3/31/07 As vs Prior

Reported Reported Year

NET REVENUES $516,440 $449,607 14.9%

Gross profit 257,725 227,300 13.4%

R&D 24,322 24,109 0.9%

S,G&A 163,116 137,073 19.0%

Arbitration and Settlement Income 0 (5,700) (100.0%)

In-Process R&D 0 9,073 (100.0%)

Operating expenses 187,438 164,555 13.9%

Operating income 70,287 62,745 12.0%

Interest expense (377) (1,256) (70.0%)

Interest income, net 5,418 7,864 (31.1%)

Other income/(expense), net 1,974 2,983 (33.8%)

Income before taxes 77,302 72,336 6.9%

Tax expense 25,322 23,227 9.0%

NET INCOME 51,980 49,109 5.8%

Net income per common share

assuming dilution $1.94 $1.78 9.4%

Weighted average number of shares

Basic 25,824 26,746

Diluted 26,746 27,649

Inc/(Dec) vs

prior year

profit

Profit Margins: margin %

Gross profit 49.9% 50.6% (0.7%)

R&D 4.7% 5.4% (0.7%)

S,G&A 31.6% 30.5% 1.1%

Operating income 13.6% 14.0% (0.4%)

Income before taxes 15.0% 16.1% (1.1%)

Net income 10.1% 10.9% (0.8%)

Revenue Analysis for Fourth Quarter FYE08 and FYE08 YTD

Fourth Quarter Twelve Months Ended

3/29/08 3/31/07 3/29/08 3/31/07

As As % Inc/ As As % Inc/

Reported Reported (Dec) Reported Reported (Dec)

Revenues by Geography

United States $62,727 $50,570 24.0% $232,812 $193,620 20.2%

International $76,012 $66,349 14.6% 283,628 255,987 10.8%

Net Revenues $138,739 $116,919 18.7% $516,440 $449,607 14.9%

Disposable Revenues by Product Family

Donor:

Plasma $40,430 $30,718 31.6% $155,219 $126,971 22.2%

Blood
'/>"/>

SOURCE Haemonetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Haemonetics Webcast Presentation
2. Keiko Hattori Joins Haemonetics as President of Haemonetics Japan
3. Haemonetics Appoints Executive Leadership of European Operations
4. Haemonetics Sets Date for Q3FY08 Earnings Release and Conference Call - January 31, 2008
5. Haemonetics(R) Reports Strong Results for Third Quarter Fiscal 2008 with Continued Double Digit Growth in Sales
6. Haemonetics(R) Software Solutions to Launch Application for Workflow Optimization in Blood Collection Centers
7. Haemonetics Sets Date for Fourth Quarter and Fiscal Year End 2008 Earnings Release and Conference Call - May 1, 2008
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Haemacure Reports Third Quarter 2007 Results
10. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly released Infusion ... technology should be used to ensure patient safety when placing an IV catheter. ... mandate the use of vein visualization technology in patients with difficult venous access ...
(Date:2/12/2016)... , ... February 12, 2016 , ... According to an ... are beginning to account for a significant portion of hernia repairs throughout the United ... the Beverly Hills Hernia Center notes that this trend has not only been expected, ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , Feb. ... , As Winston Churchill said, “Those who don’t learn from history are doomed to repeat ... when they come knocking this year. But that takes time. , Take a close ...
(Date:2/12/2016)... ... 12, 2016 , ... T.E.N., a technology and information security ... Southeast Awards 2016. Finalists and winners of the ISE® Awards for both Executive ... Awards Gala on March 15, 2016 at the Westin Peachtree Plaza, Atlanta. ...
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a locally ... a charity drive that will raise funds earmarked to purchase computers and software for ... School. , “My school is in a low-income area and has more than 60 ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... - Cardiac Marker Diagnostic ... and Cancer Therapy. - European Point of Care ... - Key Diagnostic Testing Markets. - Molecular ... Genetic Testing. - Molecular Diagnostics in Infectious Disease ... Diagnostic Products World Markets. - Point of Care ...
(Date:2/11/2016)... 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial ... 2015. The Company also filed its Quarterly Report on Form ... the Securities and Exchange Commission today. --> ... --> --> Net sales for ... or 95%, to $5.4 million from $2.8 million for the ...
(Date:2/11/2016)... OAKLAND, Calif. , Feb. 11, 2016  Walgreens ... stores across 39 states and Washington, D.C. ... in a move that was commended by shareholder advocacy organization ... President at As You Sow. "Many people hold on to ... options, which can have tragic consequences." --> ...
Breaking Medicine Technology: